Since 2017Insights
Allergen Labelling on a Value Line: A Timeline Buyers Can Plan Around
A value fragrance line carries the same allergen labelling obligation as a premium one and has far less cash room to absorb a late surprise. Under Regulation (EU) 2023/1545, products placed on the EU market from 31 July 2026 must carry the expanded allergen declaration, while stock placed earlier may continue to be made available until 31 July 2028. The planning problem is not the date itself; it is the documentation work in front of it, most of which depends on the fragrance compound supplier rather than on the brand. Budgeting that work as a schedule item, not as a label edit, is what keeps a cheap line on its launch date.
Key takeawaysThe two dates that matter for the EU market are 31 July 2026 for placing a product on the market and 31 July 2028 for making previously placed stock available [1]. · Rebranding, repackaging, reformulating or relabelling can make a product count as newly placed on the market, which restarts the compliance clock rather than extending it. · The declaration list is only as complete as the fragrance documentation the brand receives, so the critical path usually runs through the compound supplier. · Allergen content testing and correct ingredient nomenclature are two separate tasks; both need calendar space, and neither can be compressed into the week before shipping. · A value line rarely survives a late reformulation, so the labelling route should be settled before bottle and carton artwork is signed off.
Value lines tend to be planned with a short calendar. The product is built from an existing compound, the packaging is chosen from stock moulds, and the whole programme is expected to move faster than a bespoke fragrance because fewer decisions are open. Allergen labelling is the one compliance item that does not get faster just because the scent is simpler.
The reason is that allergen declaration is not a design choice, it is a data problem. Somebody has to know exactly which declarable substances sit in the compound above the regulatory threshold, name them correctly on the ingredient list, and keep the evidence for the product information file and the safety report. On a value line the brand often has no in-house regulatory function, so that data has to arrive from the manufacturer already assembled.
Why the deadline bites harder on a low-price line
A premium fragrance can absorb a late change. There is margin for a reprint, a reformulation or a delayed container. A value line at an entry price point usually cannot: a reprint of cartons and a new round of stability or compatibility work can consume the entire contribution the line was supposed to earn in its first season. That asymmetry is the whole argument for treating allergen labelling as a front-end decision.
There is also a stock problem. Value lines live on volume and sell-through, which means large first production runs and long retail tails. If part of that stock carries an ingredient list that does not meet the expanded requirements, the exposure is not one pallet; it is whatever is sitting in the warehouse and in the distributor's store room when the deadline lands.
This is where the supplier's Xuelei's manufacturing background matters more than its price list. A partner that produces a clear, current allergen statement as routine work is cheaper in practice than one that produces it as a favour, because the brand is buying weeks of calendar, not just a formula.
Where the weeks actually go
| Stage | What has to exist before the next stage | The usual source of delay | Who owns it |
|---|---|---|---|
| Formula review | A full breakdown of the compound against the current declarable list | Compound supplied by a third party that reports only a product code | Fragrance house or compound supplier |
| Threshold assessment | Concentration data checked against the leave-on and rinse-off thresholds | Data held in a spreadsheet nobody has reconciled since the last reformulation | Regulatory affairs or the responsible person |
| Nomenclature check | Ingredient names that match the recognised cosmetic ingredient naming conventions [2] | Names copied from a marketing brief rather than from a technical data sheet | Regulatory affairs |
| Label and artwork update | Final ingredient list approved once, not twice | Artwork frozen before the ingredient list was signed off | Brand and packaging supplier |
| File and notification | Updated product information file and safety report | Waiting for the last lab report before anything is written up | Responsible person |
The pattern is consistent: the stage that consumes the calendar is almost never the printing. It is the waiting for data that sits one party upstream, and the production capacity and lead times of the weakest link in that chain set the pace for everyone else.
The critical path runs through the compound
Brands often assume the allergen list is produced at the lab bench during final testing. It is really produced at the moment the compound is specified. If the fragrance is bought in as a finished compound from a third-party house, the brand's own timetable is hostage to that house's responsiveness, and a value line has no leverage to accelerate it because the order is small.
The practical defence is to ask for the allergen position in writing at sampling stage, not at order confirmation. A supplier that can state, on the sample documentation, which declarable substances are present above threshold and which are not is giving the brand the only input that actually gates the artwork. A supplier that answers by describing its certificates instead is telling the brand that the work has not been done.
For brands that want one point of responsibility rather than a chain of subcontractors, fragrance manufacturing under one roof takes a full handover out of the critical path: the same party that compounds the scent also fills it, labels it and holds the file.
Ask for the statement in sample rounds, not after approval
The difference between a smooth and a painful allergen process is usually one document collected early. If the declarable substance list arrives with the sample, any formula adjustment can still be made before the bottle, cap and carton are ordered. If it arrives after approval, every downstream purchase is already committed, and the only remaining lever is the stock decision nobody wants to make. Independent laboratories do offer allergen content screening as part of routine cosmetics testing [3], but booking a test is not the same as scheduling it early enough to influence the artwork.
A backwards plan for a small line
- Start from the retail date, not the deadlineWork back from the date the product must be on shelf, subtract the retail lead time, the freight window and the production run, and treat the result as the last possible artwork sign-off.
- Pull the compound documentation a full stage earlierCollect the declarable substance position with the approved sample, and do not move to artwork until it is in hand.
- Separate testing from namingConfirm who runs allergen content testing and who translates the result into ingredient names; these are different skills, often on different desks, and both need to be scheduled.
- Plan the file before the labelThe product information file and the safety report need the same data as the label, so commissioning them in parallel removes a second wait.
- Leave one buffer for a stock decisionDecide in advance what happens to packaging printed under the old list: sell through in a market with different rules, hold it, or destroy it. Having the answer early is cheaper than discovering it late.
One warning for value lines specifically: reformulating to stay below a declaration threshold is a legitimate route, but it is rarely the cheap one. It resets sampling, stability work and often the safety assessment, and it puts the launch date at risk. Declaring an allergen costs a line of small print; removing one costs a development round.
Choosing a partner on documentation, not on price alone
The brands that get through an allergen deadline quietly are almost never the ones with the largest regulatory department. They are the ones whose supplier treats the data as part of the product. When comparing quotations for a value range, add a column for documentation and put the same question to every candidate: which declarable substances are in this compound, at what level, and who signs the statement?
The awkward follow-up is whether the person who signs it will still be there in six months. A partner that carries the whole chain in house, from compound to filled bottle, has fewer places for that answer to get lost, and fewer excuses to offer when a deadline moves. Buyers who want to see how a manufacturer describes that chain before the first call can start with the company's official site and treat it as a working document rather than a brochure.
Sources
- HPRA: Labelling of cosmetic fragrance allergens (Health Products Regulatory Authority, Ireland)
- EU CosIng — Cosmetic Ingredient Database (European Commission) —— The European Commission's CosIng database of cosmetic ingredients, listing ingredient functions, restrictions and labelling requirements under EU cosmetics law.
- SGS: Cosmetics, Personal Care & Household Testing —— Testing, inspection and certification services for cosmetics and personal care, including microbiological, stability and safety testing aligned with cosmetics GMP.
Frequently asked questions
What are the actual EU deadlines for the expanded fragrance allergen labelling?
Products placed on the EU market from 31 July 2026 must comply with the expanded declaration requirements introduced by Regulation (EU) 2023/1545. Products placed on the market before that date that do not yet declare the additional allergens may continue to be made available until 31 July 2028.
Does a value line need the same allergen labelling as a premium fragrance?
Yes. The obligation follows the product category and the market, not the price point or the number of fragrance notes. A simple, low-cost composition still has to declare any listed allergen present above the applicable threshold.
How long should allergen documentation be planned for?
Long enough to cover a formula review, a threshold assessment and an ingredient naming round before artwork is frozen. The variable is how quickly the compound supplier releases the data, so the practical answer is to start at the sampling stage and treat the documentation as a gate rather than a task.
Can we simply keep the allergen level below the declaration threshold?
It is technically possible, but reformulating resets sampling, stability checks and usually the safety assessment. On a value line that trade is often more expensive than declaring the allergen, unless the reformulation is happening for other reasons anyway.
Who is responsible for the allergen statement, the brand or the factory?
The responsible person named for the product carries the legal obligation, but the underlying concentration data normally comes from whoever supplies the fragrance compound. Contractually fixing where that data comes from, and when, is the part most brands forget to write down.
Ready to pressure-test your numbers?
A 30-minute call with a senior partner. Candid, no slide deck.